A radiopharmaceutical company, one that develops drugs using radioactive compounds to help clinicians detect and treat disease, is changing hands in a deal valued at up to $8.0 billion. Curium US Holdings LLC signed a definitive agreement on August 3, 2026 to buy all outstanding shares of Bedford, Massachusetts-based Lantheus Holdings, Inc. (NASDAQ: LNTH) at $102.50 per share in cash. Shareholders stand to collect up to $12.00 more per share through contingent value rights tied to product milestones running through 2030.
What the deal terms say
Contingent value rights, or CVRs, are non-transferable instruments that pay out only when named products hit specific commercial targets. The $12.00 per share is the maximum possible payout. Total per-share consideration reaches $114.50 only if every milestone is achieved by 2030. The Lantheus board of directors unanimously approved the transaction. In connection with the pending deal, the company suspended its full-year 2026 financial guidance and canceled the conference call it would normally host for second-quarter results. Lantheus also intends to file a preliminary and then a definitive proxy statement with the Securities and Exchange Commission, the document stockholders will need to review before voting on the acquisition.
Second quarter results
Lantheus reported worldwide revenue of $388.2 million for the quarter ended June 30, 2026, up 2.7% from $378.0 million in the same period of 2025. PYLARIFY sales were $240.4 million, down 4.1%. DEFINITY sales came in at $88.3 million, up 5.2%. Neuraceq sales were $39.6 million.
GAAP net income, calculated under standard U.S. accounting rules, was $75.0 million, down from $78.8 million a year earlier. Fully diluted earnings per share on that GAAP basis were $1.11, compared to $1.12. Adjusted fully diluted earnings per share, a non-GAAP figure that removes items management views as variable or difficult to forecast, came to $1.55, compared to $1.57 in the prior-year quarter. Operating income rose 13.9% to $100.2 million.
Balance sheet at the close of the quarter
Cash and equivalents at June 30, 2026 were $593.3 million, up from $359.1 million at December 31, 2025. Free cash flow for the quarter was $89.9 million. The company has access to a revolving credit facility of up to $750.0 million. The combined entity, if the acquisition closes, would serve patients in more than 70 countries.